The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A long term open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or combination therapies with anti-diabetic drugs in Japanese subjects with type 2 diabetes who have inadequate glycemic control
- collapse A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea
- collapse A 24-week National Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial in India to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects with Type 2 Diabetes Who have Inadequate Glycaemic Control with Diet and Exercise alone.
- collapse Health DB Sicilia (HEALTH-DB ACS)
- collapse A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients With Cancer-Related Pain
- collapse CEPHEUS Centralized Pan-Levant Survey on the Undertreatment of Hypercholesterolemia NIS-LT-CRE-2010/01 Version 1.0
- collapse A Post Marketing Surveillance to evaluate the safety and efficacy of Brilinta
- collapse Long-tErm follow-uP of antithrombotic management patterns In Acute CORonary Syndrome patients in RUSsia
- collapse A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in The Health Improvement Network (THIN) Database in the United Kingdom (UK).
- collapse A randomised, single-blind, placebo-controlled single-centre phase I study in healthy male volunteers to assess the safety, tolerability and pharmacokinetics of AZD2820 after single ascending doses
